Nanotechnology Regulation Limited By FDA Budget Constraints – Report
This article was originally published in The Rose Sheet
Executive Summary
FDA's budget constraints and gaps in its legal authority hinder its ability to understand and manage nanotechnology's potential risks, according to Michael Taylor, a professor at the University of Maryland School of Medicine who formerly served as deputy commissioner for policy at FDA
You may also be interested in...
Michael Taylor Returns To FDA To Advise Commissioner; Agency Reorganizing
Former FDAer Michael Taylor returns to the agency as senior advisor to the commissioner, a post strikingly similar to the deputy commissioner for food position being established this month
Michael Taylor Returns To FDA To Advise Commissioner; Agency Reorganizing
Former FDAer Michael Taylor returns to the agency as senior advisor to the commissioner, a post strikingly similar to the deputy commissioner for food position being established this month
Nanotechnology Benefits/Risks Presented To FDA Nanotech Task Force
Governments, businesses and academia should take a balanced approach in developing a policy framework for nanotechnology to reap its economic and societal benefits, according to Matthew Jaffe of the Washington, D.C. law firm Crowell & Moring